National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 8 of 8 Research Studies DisplayedKohler-Forsberg O, Sylvia LG, Fung V
Adjunctive antidepressant treatment among 763 outpatients with bipolar disorder: findings from the Bipolar CHOICE and LiTMUS trials.
The purpose of this study was to examine the clinical efficacy of adjunctive antidepressants. In this large cohort of outpatients with bipolar disorder, findings showed that clinically indicated and guideline-based adjunctive antidepressant treatment was not associated with lower depressive symptoms or higher mania symptoms.
AHRQ-funded; HS019371.
Citation: Kohler-Forsberg O, Sylvia LG, Fung V .
Adjunctive antidepressant treatment among 763 outpatients with bipolar disorder: findings from the Bipolar CHOICE and LiTMUS trials.
Depress Anxiety 2021 Feb;38(2):114-23. doi: 10.1002/da.23069..
Keywords: Depression, Behavioral Health, Medication, Comparative Effectiveness, Evidence-Based Practice, Outcomes
Ochs-Ross R, Daly EJ, Zhang Y
Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression-TRANSFORM-3.
This phase 3 double-blind study randomized patients with treatment-resistant depression age 65 or older to flexibly-dosed esketamine nasal spray and new oral antidepressant (esketamine/antidepressant) or new oral antidepressant and placebo nasal spray (antidepressant/placebo). The primary endpoint was change in the Montgomery-Asberg Depression Rating Scale (MADRS) over 28 days from baseline. Results showed that esketamine/antidepressant did not achieve statistical significance for patients ages 75 and older; however, greater differences were seen for patients ages 65-74 and patients with earlier onset of depression younger than age 55.
AHRQ-funded; HS023000.
Citation: Ochs-Ross R, Daly EJ, Zhang Y .
Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression-TRANSFORM-3.
Am J Geriatr Psychiatry 2020 Feb;28(2):121-41. doi: 10.1016/j.jagp.2019.10.008..
Keywords: Medication, Depression, Behavioral Health, Elderly, Comparative Effectiveness, Treatments, Evidence-Based Practice
Wilkinson ST, Farmer C, Ballard E
Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant.
The article describes a study on the effectiveness of midazolam as a comparator in preserving the blind in ketamine studies for mood disorders. Four groups -- ketamine (midazolam-controlled), ketamine (saline-controlled), midazolam, and saline -- were compared with regard to clinical outcomes. The effect of ketamine was larger in saline-controlled studies than in midazolam-controlled studies, relative to control, but there was no difference between ketamine (midazolam-controlled) and ketamine (saline-controlled). The response rate for ketamine was higher than the control condition for both saline and midazolam.
AHRQ-funded; HS023000.
Citation: Wilkinson ST, Farmer C, Ballard E .
Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant.
Neuropsychopharmacology 2019 Jun;44(7):1233-38. doi: 10.1038/s41386-019-0317-8.
.
.
Keywords: Medication, Comparative Effectiveness, Depression, Behavioral Health, Patient-Centered Outcomes Research
Mathew SJ, Wilkinson ST, Altinay M
ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with treatment-resistant depression: The ELEKT-D study protocol.
This article discusses the protocol that will be used for an ongoing study to compare electroconvulsive therapy (ECT) vs. ketamine for patients with treatment-resistant major depressive disorder (MDD). The study is being called ELEKT-D. Patients will be randomized between thrice-weekly ECT treatments or intravenous ketamine given twice weekly for 3-5 weeks. The objective of the study is to determine if ketamine will retain 90% of the ECT treatment effect. Additional outcomes to be measured include remission rates, depression severity, cognitive functioning, quality of live, adverse events, and tolerability.
AHRQ-funded; HS023000.
Citation: Mathew SJ, Wilkinson ST, Altinay M .
ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with treatment-resistant depression: The ELEKT-D study protocol.
Contemp Clin Trials 2019 Feb;77:19-26. doi: 10.1016/j.cct.2018.12.009..
Keywords: Depression, Behavioral Health, Medication, Comparative Effectiveness, Patient-Centered Outcomes Research, Evidence-Based Practice
Wilkinson ST, Kiselycznyk C, Banasr M
Serum and plasma brain-derived neurotrophic factor and response in a randomized controlled trial of riluzole for treatment resistant depression.
In this paper, the authors report serum brain-derived neurotrophic factor (BDNF) and plasma BDNF levels from a randomized controlled, adjunctive, sequential parallel comparison design trial of riluzole in major depressive disorder. The investigators noted that preliminary evidence suggested that lower baseline BDNF may be associated with better clinical response to riluzole.
AHRQ-funded; HS023000.
Citation: Wilkinson ST, Kiselycznyk C, Banasr M .
Serum and plasma brain-derived neurotrophic factor and response in a randomized controlled trial of riluzole for treatment resistant depression.
J Affect Disord 2018 Dec 1;241:514-18. doi: 10.1016/j.jad.2018.08.075..
Keywords: Comparative Effectiveness, Depression, Medication, Patient-Centered Outcomes Research
Gartlehner G, Gaynes BN, Amick HR
Comparative benefits and harms of antidepressant, psychological, complementary, and exercise treatments for major depression: An evidence report for a clinical practice guideline from the American College of Physicians.
This evidence report compared the benefits and harms of second-generation antidepressants and psychological, complementary and alternative medicine (CAM), and exercise treatments as first- and second-step interventions for adults with acute major depressive disorder (MDD). It concluded tht, given their similar efficacy, cognitive behavioral therapy and antidepressants are both viable choices for initial treatment of MDD.
AHRQ-funded.
Citation: Gartlehner G, Gaynes BN, Amick HR .
Comparative benefits and harms of antidepressant, psychological, complementary, and exercise treatments for major depression: An evidence report for a clinical practice guideline from the American College of Physicians.
Ann Intern Med 2016 Mar 1;164(5):331-41. doi: 10.7326/m15-1813.
.
.
Keywords: Medication, Comparative Effectiveness, Complementary and Alternative Medicine, Depression, Behavioral Health
Amick HR, Gartlehner G, Gaynes BN
Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis.
This systematic review sought to identify the benefits and harms of second generation antidepressants and cognitive behavioral therapies (CBTs) in the initial treatment of a current episode of major depressive disorder in adults. It concluded that the available evidence suggests no difference in treatment effects of second generation antidepressants and CBT, either alone or in combination, although small numbers may preclude detection of small but clinically meaningful differences.
AHRQ-funded; 290-2012-00008I
Citation: Amick HR, Gartlehner G, Gaynes BN .
Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis.
BMJ 2015 Dec 8;351:h6019. doi: 10.1136/bmj.h6019..
Keywords: Medication, Behavioral Health, Comparative Effectiveness, Depression
Bobo WV, Reilly-Harrington NA, Ketter TA
Effect of adjunctive benzodiazepines on clinical outcomes in lithium- or quetiapine-treated outpatients with bipolar I or II disorder: results from the Bipolar CHOICE trial.
This study investigated the longer-term effects of adjunctive benzodiazepines on symptom response during treatment in patients with bipolar disorders. The investigators concluded that adjunctive benzodiazepines may not significantly affect clinical outcome in lithium- or quetiapine-treated patients with bipolar I or II disorder over 6 months, after controlling for potential confounding factors.
AHRQ-funded; HS019371.
Citation: Bobo WV, Reilly-Harrington NA, Ketter TA .
Effect of adjunctive benzodiazepines on clinical outcomes in lithium- or quetiapine-treated outpatients with bipolar I or II disorder: results from the Bipolar CHOICE trial.
J Affect Disord 2014 Jun;161:30-5. doi: 10.1016/j.jad.2014.02.046..
Keywords: Comparative Effectiveness, Depression, Medication, Behavioral Health, Treatments